60
Participants
Start Date
January 1, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Zeposia
Participants with MS will be divided into two treatment groups: those who will begin to take Zeposia, and those who plan to be begin treatment with high dose oral efficacy medication. The HC group will be free of neurological disease or injury and will be matched to the MS groups for age, gender, and education.
RECRUITING
Kessler Foundation, West Orange
Lead Sponsor
Collaborators (1)
Celgene
INDUSTRY
Hackensack Meridian Health
OTHER
St. Barnabas Medical Center
OTHER
Kessler Foundation
OTHER